3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
5
Phase 3
2
Phase 2
1
Phase 1
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
12
Breast
11
Other hematologic neoplasm
7
Gastrointestinal
7
Thoracic
6
Lymphoid
6
Head & Neck
6
Tumor-Agnostic
2
Sarcoma
2
Other
2
Gynecologic
2
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
1
Endometrial Clear Cell Adenocarcinoma
1
Interventions
Doxorubicin
40
Radiotherapy
30
Ifosfamide
28
Vincristine
27
Cyclophosphamide
24
Imatinib Mesylate
20
Etoposide
20
Dactinomycin
14
Radiation
13
Filgrastim
11
Temozolomide
9
Sunitinib
9
Trabectedin
8
Methotrexate
8
Specimen Handling
7
Magnetic Resonance Spectroscopy
6
Granulocyte Colony-Stimulating Factor
6
Chemotherapy, Adjuvant
6
pazopanib
5
nilotinib
5
Zoledronic Acid
5
Neoadjuvant Therapy
5
Irinotecan
5
Cisplatin
5
Carboplatin
5
X-Rays
4
Vinorelbine
4
Topotecan
4
Surgical Procedures, Operative
4
Procarbazine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Standard of Care
×
Sarcoma
×
Clear all
NCT04307277
2026-04-14
CHIC-STS01
Institut Claudius Regaud
Phase 3
Recruiting
600 enrolled
NCT03422198
2025-12-12
SAVE
University of Utah
Phase 3
Recruiting
188 enrolled
15 charts